Frank Vinluan from MedCity News - Journalist Profile

	Profile	Contacts	Recent Articles on Subject
1	Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA medicalinnovation		ASH 2024 Recap: Movement in Multiple Myeloma, Cell Therapy, Sickle Cell Disease & More - 8 days ago AI Biotech BenevolentAI Restructures Again, This Time to Return to Its TechBio Roots - 9 days ago Safety Stands Out in Arcellx Cell Therapy’s ASH Data, But Don’t Overlook Manufacturing Advantages - 10 days ago GSK Multiple Myeloma Drug’s DREAMM Comeback Continues With Phase 3 Data at ASH - 11 days ago Safety Signal in Phase 2 Deals a Setback to BioAge Labs’ Muscle-Preserving Obesity Drug - 13 days ago Nuvig Therapeutics Nabs $161M to Build Case for a Better Approach to Autoimmune Disease - 15 days ago Eli Lilly’s Zepbound Leads to Greater Weight Loss vs. Novo Nordisk Drug in Head-to-Head Test - 16 days ago Takeda Pays $200M for Keros Therapeutics Drug With Potential in Blood Cancers and Beyond - 17 days ago Novartis Tries Again in Huntington’s, Putting Up $1B to Partner on a PTC Therapeutics Drug - 18 days ago Applied Therapeutics Drug Is Denied FDA Approval in Rare Inherited Metabolic Disease - 18 days ago Startup OncoSwab Aims to Make Lung Cancer Detection as Simple as Flu & Covid-19 Tests - 19 days ago Weight Loss With Amgen Drug in Line With Eli Lilly Med, But Dosing Could Be Differentiator - 24 days ago Roche Expands Its Scope in Allogeneic Cell Therapy With $1B Poseida Therapeutics Acquisition - 24 days ago FDA Nod for BridgeBio Brings New Competition to Blockbuster Pfizer Cardio Drug - 25 days ago Halozyme Pulls €2B Acquisition Bid as Evotec Commits to Standalone Strategy - 27 days ago Patient Dies in Gene Therapy Trial, But FDA Permits Neurogene to Proceed With Low Dose - 28 days ago Kura Oncology Gets $330M to Kick Off Global Leukemia Drug Pact With Kyowa Kirin - 29 days ago Startup Valora Unveils a Sweet Way to Stop Cancer and Autoimmune Disease, Plus $30M for R&D - about 1 month ago Merck Gets a Shot of Confidence From Pivotal Test of SubQ Injectable Keytruda - about 1 month ago Syndax Pharmaceuticals Leukemia Drug Wins a First-in-Class FDA Approval - about 1 month ago GSK Wagers $80M on a Tech Platform and Parkinson’s Drug from Flagship-Founded Vesalius - about 1 month ago Halozyme Makes Unsolicited €2B Takeover Bid for Drug R&D Services Firm Evotec - about 1 month ago PTC Therapeutics Wins First FDA Approval for a Gene Therapy Dosed Directly Into the Brain - about 1 month ago Merck Is Paying $588M for Potential Successor to Cancer Drug Juggernaut Keytruda - about 1 month ago Johnson & Johnson Takes the 340B Drug Rebate Fight to Federal Court - about 1 month ago AbbVie Drug Expected to Rival Bristol Myers’s New Schizophrenia Med Flunks Phase 2 Test - about 1 month ago ‘Serial Killing’ Cell Therapy From Autolus Lands FDA Approval in Blood Cancer - about 1 month ago FDA Takes Step Toward Removal of Ineffective Decongestants From the Market - about 1 month ago Private Equity Is Picking Up Biologics CDMO Avid Bioservices in $1.1B Acquisition - about 1 month ago Acadia Pharma Sells Voucher for Speedier FDA Drug Review for $150M - about 1 month ago Beam’s Base-Editing Sickle Cell Therapy Shows Early Promise, But a Fatality Overshadows Results - about 2 months ago Novo Nordisk Commits $285M to Ascendis to Kick Off Alliance on Longer-Acting GLP-1 Drugs - about 2 months ago Viking Therapeutics’ Early Clinical Data Continue to Build Case for Its Oral Obesity Drug - about 2 months ago Protein-Design Startup Archon Adds $20M to Show How ‘Cages’ Can Change Antibody Drugs - about 2 months ago Novo Nordisk GLP-1 Drug Meets Goals of MASH Trial, Setting Stage for FDA & EMA Filings - about 2 months ago Precision Oncology Startup Kivu Unveils $92M for More Stable & Durable ADC Cancer Drugs - about 2 months ago Biogen, Sage Therapeutics Drop Plans to Develop Partnered Drug in Major Depressive Disorder - about 2 months ago Going In Reverse Is Faster Way Forward for Crescent Bio’s Cancer Immunotherapy - about 2 months ago AbbVie Adds Another Alzheimer’s Prospect With $1.4B Aliada Therapeutics Acquisition - about 2 months ago Novartis to Pay $150M for Monte Rosa Glue Drug in the Clinic for Immunology Indications - about 2 months ago Seaport Therapeutics Secures $225M for New Kind of Depression Drug - about 2 months ago Septerna’s Upsized IPO Brings In $288M to Support a Pipeline of GPCR Drugs - about 2 months ago Gates Foundation Joins Radiant Bio’s $35M Round for Antibody Drugs With ‘Better Grip’ - about 2 months ago Alto Neuroscience’s Depression Trial Failure Sends Shares Into Downward Spiral - about 2 months ago Editas Medicine Seeks Partner for Ex Vivo Gene-Editing Program as Focus Turns to In Vivo R&D - about 2 months ago Astellas Pharma Lands a First-in-Class Drug Approval in Rare Gastrointestinal Cancer - 2 months ago How Generative AI Will Find a Place in the Pharma Industry Now and in the Years to Come - 2 months ago Gilead Sciences Voluntarily Pulls Drug for Bladder Cancer After Trial Failure - 2 months ago Sanofi Puts Up €300M in New Targeted Radiation Cancer Therapy Pact With Orano - 2 months ago Wearable Tumor-Zapping Medical Device Wins FDA Approval for Lung Cancer - 2 months ago